Terms: = Head and neck cancer AND CALCB, Calcitonin AND Treatment
611 results:
1. Sensory nerve release of CGRP increases tumor growth in HNSCC by suppressing TILs.
Darragh LB; Nguyen A; Pham TT; Idlett-Ali S; Knitz MW; Gadwa J; Bukkapatnam S; Corbo S; Olimpo NA; Nguyen D; Van Court B; Neupert B; Yu J; Ross RB; Corbisiero M; Abdelazeem KNM; Maroney SP; Galindo DC; Mukdad L; Saviola A; Joshi M; White R; Alhiyari Y; Samedi V; Van Bokhoven A; St John M; Karam SD
Med; 2024 Mar; 5(3):254-270.e8. PubMed ID: 38423011
[TBL] [Abstract] [Full Text] [Related]
2. Extent of Surgery for Medullary Thyroid cancer and Prevalence of Occult Contralateral Foci.
Mao YV; Hughes EG; Steinmetz D; Troob S; Kim J; Tseng CH; Fishbein GA; Sajed DP; Livhits MJ; Yeh MW; Lee D; Angell TE; Wu JX
JAMA Otolaryngol Head Neck Surg; 2024 Mar; 150(3):209-214. PubMed ID: 38270925
[TBL] [Abstract] [Full Text] [Related]
3. [Precision medicine in endocrinology exemplified by medullary thyroid cancer].
Brandenburg T; Machlah YM; Führer D
Inn Med (Heidelb); 2024 Mar; 65(3):202-210. PubMed ID: 38231404
[TBL] [Abstract] [Full Text] [Related]
4. [Individualization of treatment in sporadic and hereditary medullary thyroid cancer].
Lorenz K; Machens A; Dralle H
Chirurgie (Heidelb); 2024 Mar; 95(3):186-191. PubMed ID: 38214736
[TBL] [Abstract] [Full Text] [Related]
5. Efficacy and Toxicity of calcitonin treatment in Children with Cherubism: A Single-Center Cohort Study.
Schreuder WH; Meijer EB; Cleven AHG; Edelenbos E; Klop C; Schreurs R; de Jong RT; van Maarle MC; Horsthuis RBG; de Lange J; van den Berg H
J Bone Miner Res; 2023 Dec; 38(12):1822-1833. PubMed ID: 37823782
[TBL] [Abstract] [Full Text] [Related]
6. Risk factors for cervical lymph node metastasis in the central or lateral cervical region in medullary thyroid carcinoma: a systematic review and meta-analysis.
Lin X; Huo J; Su H; Zhu C; Xu Y; Zhang F
Eur Arch Otorhinolaryngol; 2024 Feb; 281(2):547-561. PubMed ID: 37801162
[TBL] [Abstract] [Full Text] [Related]
7. Exploring the application value of pro-gastrin-releasing peptide in the clinical diagnosis and surgical treatment of medullary thyroid carcinoma.
Miao Q; Lv X; Luo L; Zhang J; Cai B
Cancer Med; 2023 Oct; 12(19):19576-19582. PubMed ID: 37754747
[TBL] [Abstract] [Full Text] [Related]
8. [calcitonin measurement in fine-needle washout fluids in detecting medullary thyroid cancer].
Zuraeva ZT; Nikankina LV; Kolesnikova GS; Abdulhabirova FM; Beltsevich DG; Malysheva NM; Mikheenkov AA
Probl Endokrinol (Mosk); 2023 Jun; 69(3):9-15. PubMed ID: 37448242
[TBL] [Abstract] [Full Text] [Related]
9. CD276 as a Candidate Target for Immunotherapy in Medullary Thyroid cancer.
Hińcza-Nowak K; Kowalik A; Walczyk A; Pałyga I; Gąsior-Perczak D; Płusa A; Kopczyński J; Chrapek M; Góźdź S; Kowalska A
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373167
[TBL] [Abstract] [Full Text] [Related]
10. Validation of miRNAs as diagnostic and prognostic biomarkers, and possible therapeutic targets in medullary thyroid cancers.
Mondin A; Bertazza L; Barollo S; Pedron MC; Manso J; Piva I; Basso D; Merante Boschin I; Iacobone M; Pezzani R; Mian C; Censi S
Front Endocrinol (Lausanne); 2023; 14():1151583. PubMed ID: 37361540
[TBL] [Abstract] [Full Text] [Related]
11. Radioactive iodine in the management of medullary carcinoma of the thyroid.
Rowell NP
Br J Radiol; 2023 Aug; 96(1148):20220660. PubMed ID: 37335288
[TBL] [Abstract] [Full Text] [Related]
12. Medullary Thyroid cancer: Updates and Challenges.
Gild ML; Clifton-Bligh RJ; Wirth LJ; Robinson BG
Endocr Rev; 2023 Sep; 44(5):934-946. PubMed ID: 37204852
[TBL] [Abstract] [Full Text] [Related]
13. Natural History and Predictive Factors of Outcome in Medullary Thyroid Microcarcinoma.
Kesby N; Mechera R; Fuchs T; Papachristos A; Gild M; Tsang V; Clifton-Bligh R; Robinson B; Sywak M; Sidhu S; Chou A; Gill AJ; Glover A
J Clin Endocrinol Metab; 2023 Sep; 108(10):2626-2634. PubMed ID: 36964913
[TBL] [Abstract] [Full Text] [Related]
14. Clinical Evolution of Sporadic Medullary Thyroid Carcinoma With Biochemical Incomplete Response After Initial treatment.
Prete A; Gambale C; Torregrossa L; Ciampi R; Romei C; Ramone T; Agate L; Bottici V; Cappagli V; Molinaro E; Materazzi G; Elisei R; Matrone A
J Clin Endocrinol Metab; 2023 Jul; 108(8):e613-e622. PubMed ID: 36722192
[TBL] [Abstract] [Full Text] [Related]
15. Update on Management of Medullary Thyroid Carcinoma: Focus on Nuclear Medicine.
Treglia G; Rufini V; Piccardo A; Imperiale A
Semin Nucl Med; 2023 Jul; 53(4):481-489. PubMed ID: 36702731
[TBL] [Abstract] [Full Text] [Related]
16. Other markers of medullary thyroid cancer, not only calcitonin.
Censi S; Manso J; Mian C
Eur J Endocrinol; 2023 Jan; 188(1):. PubMed ID: 36651167
[TBL] [Abstract] [Full Text] [Related]
17. Early postoperative calcitonin-to-preoperative calcitonin ratio as a predictive marker for structural recurrence in sporadic medullary thyroid cancer: A retrospective study.
Jiao Z; Wu T; Jiang M; Jiang S; Jiang K; Peng J; Luo G; Yu Y; Chen W; Yang A
Front Endocrinol (Lausanne); 2022; 13():1094242. PubMed ID: 36589824
[TBL] [Abstract] [Full Text] [Related]
18. A Systematic Review Supporting the Endocrine Society Clinical Practice Guideline on the treatment of Hypercalcemia of Malignancy in Adults.
Seisa MO; Nayfeh T; Hasan B; Firwana M; Saadi S; Mushannen A; Shah SH; Rajjoub NS; Farah MH; Prokop LJ; Wang Z; Fuleihan GE; Drake MT; Murad MH
J Clin Endocrinol Metab; 2023 Feb; 108(3):585-591. PubMed ID: 36545700
[TBL] [Abstract] [Full Text] [Related]
19. [Risk factors of recurrence or metastasis in patients with medullary thyroid carcinoma].
Guo FL; Li LJ; Ruan XH; Fu GM; Zhao JZ; Hou XK; Gao M; Zheng XQ
Zhonghua Yi Xue Za Zhi; 2022 Dec; 102(48):3849-3855. PubMed ID: 36540922
[No Abstract] [Full Text] [Related]
20. Oncologic outcomes of calcitonin-negative medullary thyroid carcinoma.
Yue W; Zhang Y
Front Endocrinol (Lausanne); 2022; 13():1025629. PubMed ID: 36506082
[TBL] [Abstract] [Full Text] [Related]
[Next]
